Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib Plus Chemotherapy in BCR/ABL1-Like ALL
NCT05306301Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Started Oct 2022; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05306301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306301.